Answers are grounded in this paper and cite their sources.
Introduction: Central pontine myelinolysis (CPM) is usually associated with rapid correction of hyponatremia but may occur in normonatremic patients. Its occurrence during isonatric haemodialysis raises questions about metabolic vulnerability. Case description: A 65-year-old man receiving maintenance haemodialysis since 2020, subsequently managed with an isonatric strategy, developed progressive tremors, dizziness, gait instability, falls, and cognitive impairment. Brain magnetic resonance imaging in August 2023 revealed a central pontine lesion suggestive of CPM, which was unchanged in April 2024. Previous imaging during an ischemic stroke in 2021 showed no pontine lesion. Predialysis sodium ranged from 138 to 143 mmol/l, without documented rapid correction. Recurrent postdialysis hypokalemia (minimum 3.1 mmol/l), hypoalbuminemia (23 g/l), low prealbumin (12 mg/dl), and inflammation (C-reactive protein 153.4 mg/l) were documented. In June 2024, propranolol, potassium supplementation, and intradialytic parenteral and oral nutritional support were initiated. In July, albumin reached 37.7 g/l, prealbumin 23.6 mg/dl, and C-reactive protein 4.9 mg/l. Treatment was well tolerated. Tremors improved, and the patient regained independence. Discussion: Recurrent hypokalemia and nutritional and inflammatory abnormalities may increase susceptibility to osmotic demyelination despite limited sodium fluctuations. However, their causal contribution remains uncertain. Conclusion: CPM should be considered in haemodialysis patients with progressive neurological symptoms, even without documented hyponatremia.
No takes yet. Share an insight, caveat, or question.
Bunkete et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: